logo-loader
viewLexagene Holdings Inc

Full interview: LexaGene teams up with Assurance Scientific to beta test its diagnostic in humans

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Dr Jack Regan notes that the firm is teaming up with Assurance Scientific Laboratories (ASL) to test its rapid pathogen detection technology on human urine samples. Dr Regan says ASL has the ability to bring LexaGene's diagnostic in-house, validate it, and begin using it for clinical diagnostic.

Quick facts: Lexagene Holdings Inc

Price: 0.57 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $48.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 17/9/19

2 min read